This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Overview
The EGPA Collaborative: Cases of Appropriate Multidisciplinary Management

The EGPA Collaborative: Cases of Appropriate Multidisciplinary Management

Format

Clinical Review

Time to Complete

1 hour

Released

June 20, 2019

Expires

June 20, 2020
Start Activity
Add to Queue


Maximum Credits

1.00 / AMA PRA Category 1 CreditTM
1.00 / ABIM MOC Part II point

An important note about ABIM MOC Part II points
Successful completion of this CME activity enables eligible participants to earn up to 1.00 ABIM-Part II Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Once you have completed the activity there will be an opportunity to click through to submit your request this credit. To claim MOC points, follow these easy steps:

Step 1: Complete all the questions within the link provided under the "ABIM Part 2 Credit Questions" section.

Step 2: Our partner, AKH Inc., Advancing Knowledge in Healthcare, will send your MOC points to your ABIM account within 6-8 weeks.

Accredited Provider




Provided by Advancing Knowledge in Healthcare (AKH) Inc.

Collaborator



In collaboration with the American Thoracic Society

Commercial Supporter

This educational activity is supported by an educational grant from GlaxoSmithKline.

Program Description

This is the first of 2 one-hour webinars on EGPA, each led by 3 experts in EGPA. This first program will address the diagnosis, treatment initiation and long-term monitoring of this rare eosinophilic disorder. EGPA affects many organ systems; consequently a wide range of clinicians may be involved in the diagnosis and management of these patients. Faculty will review the clinical manifestations of EGPA from both rheumatologic and pulmonary perspectives, including how EGPA is similar to and differs from other vasculitides. Greater understanding of this disease has led to the development and approval of mepolizumab, the first agent specifically indicated for EGPA. A second webinar will integrate this foundational information into clinical practice through the use of case studies.

Intended Audience

This activity is intended for Pulmonologists, Rheumatologists, Primary Care Physicians, Allergists/Immunologists, Dermatologists, and other health care professionals who manage patients with EGPA.

Educational Objectives

After completing this activity, participants should be able to:

  • Review the clinical presentation and signs and symptoms of EGPA
  • Describe the ANCA-associated vasculitides
  • Describe the diagnostic evaluation of EGPA
  • Identify treatment options for initial therapy and for recalcitrant disease

Conflict Of Interest Disclosure Policy

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. AKH Inc., Advancing Knowledge in Healthcare, planners and reviewers have no relevant financial relationships to disclose.

Faculty

Praveen Akuthota, MD
Associate Professor of Medicine
University of California San Diego
San Diego, CA

Dr. Akuthota has disclosed the following relevant financial relationships:
Consultant: AstraZeneca, GlaxoSmithKline
Contracted Research: AstraZeneca, GlaxoSmithKline

Philip Seo, MD, MHS
Director, The Johns Hopkins Vasculitis Center
Johns Hopkins University
Director, Johns Hopkins Rheumatology Fellowship
Johns Hopkins University
Baltimore, MD

Dr. Seo has disclosed no financial relationships.

Michael E. Wechsler, MD
Professor of Medicine
Director, NJH Cohen Family Asthma Institute
National Jewish Health
Denver, CO

Dr. Wechsler has disclosed the following relevant financial relationships:
Consultant: AstraZeneca, Boehringer Ingelheim, Glaxosmithkline, Novartis, Regneeron, Sanofi, Teva
Contracted Research: AstraZeneca, Novartis, Sanofi, Teva

Accredited Provider Disclosure

Lynne Kolton Schneider, PhD, Medical Writer/Interviewer, has discloses no financial relationships.
Dorothy Caputo, MA, BSN, RN, Director of Accreditation, Planner, has discloses no financial relationships.
Patricia Brignoni, AKH Sr. Project Manager, has discloses no financial relationships.
Steve Eckert, AKH President & CEO, Planner, has discloses no financial relationships.

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

AKH Inc., Advancing Knowledge in Healthcare is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 CreditTM  .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Part II Point

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure of Unlabeled Use

This educational activity will include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Instructions

To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. You must participate in the entire activity to receive credit. IfYour online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

If you have any questions relating to the accreditation of this activity, please contact AKH at tbrignoni@akhcme.com.

Privacy Policy

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Start Activity
Add to Queue


© 2020 Haymarket Media, Inc.


HME and myCME are divisions of Haymarket Media, Inc., a General Services Administration (GSA) Contract Holder

Your use of this website constitutes acceptance of Haymarket Medical Education's Privacy Policy and Terms & Conditions

Haymarket Medical Education